LOURY DAVID J,HEDRICK ERIC,ELIAS LAURENCE,MODY TARAK D,FYFE GWEN,BUGGY JOSEPH J
申请号：
NZ70248511
公开号：
NZ702485A
申请日:
2011.06.03
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed is the use of the inhibitor of Bruton&rsquo；s tyrosine kinase (Btk) (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one / ibrutinib / PCI-32765 in the preparation of a medicament for treating Waldenstrom&rsquo；s macroglobulinemia in an individual wherein, the medicament comprises from 420mg to 840mg of said inhibitor, the medicament is formulated for oral administration, and said individual has already received at least one prior therapy for Waldenstrom&rsquo；s macroglobulinemia.
